Boston jury rules against Roche in Mircera case

BOSTON A jury in a federal court in Boston has ruled that Roche Holding’s pegylated-erythropoietin product Mircera infringes 11 Amgen patents.

Amgen plans to seek an injunction to prevent Roche from marketing its Mircera product in the U.S. Recently, during an earnings call, Roche had indicated an Amgen win would “probably block” a Mircera launch.

The injunction hearing in set for Nov. 15.